PRMT5 and prostate carcinoma: Remarkably, in a bioluminescent imaging (BLI)-based lung metastasis mouse model, established by tail vein injection of prostate cancer cells with stable ZMYND11 knockdown, treatment with PRMT5 inhibitors EPZ015666 or GSK3326595 substantially reduced lung metastasis (Fig. 8h-j).